• 1
    Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994; 331: 896-903.
  • 2
    Glucksberg H, Cheever MA, Farewell VT, Fefer A, Sale GE, Thomas ED. High-dose combination chemotherapy for acute nonlymphoblastic leukemia in adults. Cancer. 1981; 48: 1073-1081.
  • 3
    Preisler HD, Rustum Y, Henderson ES, et al. Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood. 1979; 53: 455-464.
  • 4
    Phillips GL, Reece DE, Shepherd JD, et al. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood. 1991; 77: 1429-1435.
  • 5
    Tricot G, Boogaerts MA, Vlietinck R, Emonds MP, Verwilghen RL. The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia. Br J Haematol. 1987; 66: 37-44.
  • 6
    Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992; 79: 313-319.
  • 7
    Blaise D, Maraninchi D, Archimbaud E, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood. 1992; 79: 2578-2582.
  • 8
    Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood. 1993; 81: 311-318.
  • 9
    Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998; 339: 1649-1656.
  • 10
    Peterson BA, Bloomfield CD. Long-term disease-free survival in acute nonlymphocytic leukemia. Blood. 1981; 57: 1144-1147.
  • 11
    Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981; 58: 1203-1212.
  • 12
    Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood. 1983; 62: 315-319.
  • 13
    Peterson BA, Bloomfield CD. Prolonged maintained remissions of adult acute non-lymphocytic leukaemia. Lancet. 1977; 2: 158-160.
  • 14
    Passe S, Miké V, Mertelsmann R, Gee TS, Clarkson BD. Acute nonlymphoblastic leukemia: prognostic factors in adults with long-term follow-up. Cancer. 1982; 50: 1462-1471.
  • 15
    Velu T, Debusscher L, Stryckmans P. Daunorubicin in patients with relapsed and refractory acute nonlymphoblastic leukemia previously treated with anthracycline. Am J Hematol. 1988; 27: 224-225.
  • 16
    Willemze R, Zwaan FE, Colpin G, Keuning JJ. High dose cytosine arabinoside in the management of refractory acute leukaemia. Scand J Haematol. 1982; 29: 141-146.
  • 17
    Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP. High-dose cytosine arabinoside therapy for refractory leukemia. Blood. 1983; 62: 361-369.
  • 18
    Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GP. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol. 1985; 3: 992-997.
  • 19
    Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010; 28: 3730-3738.
  • 20
    Coleman PJ, Fraley ME. Inhibitors of the mitotic kinesin spindle protein. Expert Opin Ther Patents. 2004; 14: 1659-1667.
  • 21
    Vale RD, Milligan RA. The way things move: looking under the hood of molecular motor proteins. Science. 2000; 288: 88-95.
  • 22
    Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol. 2000; 150: 975-988.
  • 23
    Sawin KE, LeGuellec K, Philippe M, Mitchison TJ. Mitotic spindle organization by a plus-end-directed microtubule motor. Nature. 1992; 359: 540-543.
  • 24
    Blangy A, Lane HA, d'Hérin P, Harper M, Kress M, Nigg EA. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell. 1995; 83: 1159-1169.
  • 25
    Sakowicz R, Finer JT, Beraud C, et al. Antitumor activity of a kinesin inhibitor. Cancer Res. 2004; 64: 3276-3280.
  • 26
    Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999; 286: 971-974.
  • 27
    Cox CD, Breslin MJ, Mariano BJ, et al. Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett. 2005; 15: 2041-2045.
  • 28
    Lobell J, Deihl R, Mahan E, et al. In vivo characterization of an inhibitor of the mitotic kinesin, KSP: pharmacodynamics, efficacy, and tolerability in xenograft tumor models [Abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; November 14-18, 2005; Philadelphia, PA. Abstract B189.
  • 29
    Gonzales P, Bienek A, Piazza G, et al. Breadth of anti-tumor activity of CK0238273 (SB-715992), a novel inhibitor of the mitotic kinesin KSP [Abstract]. In: Proceedings of the American Association for Cancer Research 93rd Annual Meeting; April 6-10, 2002; San Francisco, CA. Abstract 1337.
  • 30
    Johnson R, Caulder E, Inlow-Porter L, et al. A potent and selective inhibitor of the mitotic kinesin KSP, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts [Abstract]. In: Proceedings of the American Association for Cancer Research 93rd Annual Meeting; April 6-10, 2002; San Francisco, CA. Abstract 1335.
  • 31
    Woessner R, Tunquist B, Lemieux C, et al. ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models. Anticancer Res. 2009; 29: 4373-4380.
  • 32
    Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108: 419-425.
  • 33
    Zhang S, Schafer-Hales K, Khuri FR, Zhou W, Vertino PM, Marcus AI. The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity. Cancer Res. 2008; 68: 740-748.
  • 34
    Marcus AI, Peters U, Thomas SL, et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J Biol Chem. 2005; 280: 11569-11577.
  • 35
    Tunquist BJ, Woessner RD, Walker DH. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. Mol Cancer Ther. 2010; 9: 2046-2056.
  • 36
    Gomez HL, Castaneda C, Pimentel P, et al. A phase I/II trial of ispinesib, a kinesin spindle protein (KSP) inhibitor, dosed q14d in patients with advanced breast cancer previously untreated with chemotherapy for metastatic disease or recurrence. J Clin Oncol. 2009; 27( suppl): 15s (abstract 1077).